Research programme: histone based cancer therapeutics - SymbioTecAlternative Names: Histone H1.2
Latest Information Update: 09 Jul 2010
At a glance
- Originator SymbioTec
- Class Recombinant proteins
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 25 Aug 2004 Preclinical trials in Cancer in Germany (unspecified route)